BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 27315757)

  • 21. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
    Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
    Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
    Carey RM
    Curr Cardiol Rep; 2016 Oct; 18(10):97. PubMed ID: 27566330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
    Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
    Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of primary aldosteronism with a negative aldosterone-to-renin ratio.
    Liu F; Wang L; Ding Y
    BMC Cardiovasc Disord; 2021 Jul; 21(1):350. PubMed ID: 34294029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
    Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
    Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary hyperaldosteronism diagnosed with adrenal vein sampling. Characteristics and follow-up after adrenalectomy in a Danish study.
    Pedersen M; Karlsen MA; Ankjærgaard KL; Jensen LT
    Scand J Clin Lab Invest; 2016; 76(1):45-50. PubMed ID: 26471096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The aldosterone/renin ratio as a screening test for primary aldosteronism.
    Rayner BL; Opie LH; Davidson JS
    S Afr Med J; 2000 Apr; 90(4):394-400. PubMed ID: 10957926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients.
    Hyla-Klekot L; Kokot F
    Pol Arch Med Wewn; 2013; 123(10):547-51. PubMed ID: 24104388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of Aldosterone Secretion After Recumbent Saline Infusion Does Not Exclude Lateralized Primary Aldosteronism.
    Cornu E; Steichen O; Nogueira-Silva L; Küpers E; Pagny JY; Grataloup C; Baron S; Zinzindohoue F; Plouin PF; Amar L
    Hypertension; 2016 Oct; 68(4):989-94. PubMed ID: 27600182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary aldosteronism: Practical recommendations for treatment and follow-up.
    Araujo-Castro M; Pascual-Corrales E; Martín Rojas P; Parra Ramírez P
    Hipertens Riesgo Vasc; 2023; 40(4):215-221. PubMed ID: 37993292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The difficulties in differential diagnosis of primary aldosteronism subtypes in women with strokes at a young age].
    Bohdanowicz-Pawlak A; Szymczak J; Jakubowska J; Brona A
    Endokrynol Pol; 2009; 60(6):492-6. PubMed ID: 20041369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting and treating primary aldosteronism: primary aldosteronism.
    Mantero F; Mattarello MJ; Albiger NM
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):171-4. PubMed ID: 17427105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine.
    Niizuma S; Nakahama H; Kamide K; Fukuchi K; Iwanaga Y; Nakata H; Yoshihara F; Horio T; Nakamura S; Kawano Y
    Clin Exp Hypertens; 2008 Oct; 30(7):640-7. PubMed ID: 18855267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
    Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
    J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary aldosteronism in pregnancy.
    Forestiero V; Sconfienza E; Mulatero P; Monticone S
    Rev Endocr Metab Disord; 2023 Feb; 24(1):39-48. PubMed ID: 35536535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].
    Chen SX; Du YL; Zhang J; Gong YC; Hu YR; Chu SL; He QB; Song YY; Zhu DL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):868-72. PubMed ID: 17217708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism.
    Rye P; Chin A; Pasieka J; So B; Harvey A; Kline G
    J Clin Hypertens (Greenwich); 2015 Jul; 17(7):541-6. PubMed ID: 25756935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.